Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem® by UNICEF to Support Vaccination Programs in the Developing World
(Thomson Reuters ONE) -
Leiden, the Netherlands (May 6, 2010) - Dutch biopharmaceutical company Crucell
N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced the
award from UNICEF of an additional $110 million to supply its paediatric vaccine
Quinvaxem(®) to the developing world.
Paediatric vaccination plays an important role in contributing to achieving the
Millennium Development Goals set by the United Nations, in particular the target
of reducing under-five mortality rate by two-thirds between 1990 and 2015.
"We are proud to be able to deliver significant amount of additional vaccine
orders at short notice," said Ronald Brus, Crucell's Chief Executive Officer.
"The capacity and reliability of Crucell's manufacturing and logistical systems
allows us to deliver high quality and safe vaccines to protect young children
from life threatening diseases in the world's developing countries. As a
responsible and reliable partner, we thus contribute to the success of the
Global Alliance for Vaccines and Immunisation (GAVI Alliance) in accelerating
access to these vaccines across the globe."
From 2006-2009 as part of the Extended Program for Immunization, over 130
million doses of Quinvaxem(®) have been delivered to more than 50 countries.
Crucell has been increasing its production capacity over the last few years in
order to meet the growing demand for paediatric vaccines from the developing
world.
Quinvaxem(®) is the only fully liquid pentavalent DTwP-HepB-Hib vaccine that is
free from the preservative thiomersal. It is an optimal solution for protection
against five potentially deadly childhood diseases: diphtheria, tetanus,
pertussis, Haemoplilus influenza type b infection and hepatitis B. Quinvaxem(®)
is ready for use without further preparation steps by healthcare workers in the
field, which offers major healthcare advantages for these countries with a
challenging infrastructure and hygiene problems.
This latest order brings the overall value of tenders awarded to Crucell for the
period of 2010-2012 to $410 million. This is in addition to the $500 million
obtained over the tender period 2007-2009. They bring the total value of
contracts awarded since the launch of Quinvaxem(®) at the end of 2006 to $910
million. During the first tender round in 2006, Crucell was initially awarded
$230 million (December 2006) and received additional incremental awards of $130
million and $140 million in May and September 2008, respectively.
Forward-looking statements
This press release contains forward-looking statements that involve inherent
risks and uncertainties. We have identified certain important factors that may
cause actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors please
refer to our Form 20-F, as filed with the US Securities and Exchange Commission
on April 7, 2010, in the section entitled 'Risk Factors'. The Company prepares
its financial statements under International Financial Reporting Standards
(IFRS).
About Crucell
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global
biopharmaceutical company focused on research development, production and
marketing of vaccines, proteins and antibodies that prevent and/or treat
infectious diseases. In 2009 alone, Crucell distributed more than 115 million
vaccine doses in more than 100 countries around the world, with the fast
majority of doses (97%) going to developing countries. Crucell is one of the
major suppliers of vaccines to UNICEF and the developing world. Crucell was the
first manufacturer to launch a fully-liquid pentavalent vaccine called
Quinvaxem(®). Quinvaxem(®) protects against five important childhood diseases
and over 130 million doses have been sold since its launch in 2006 in more than
50 GAVI countries. Through Quinvaxem(®) and its innovation, Crucell has become a
major partner in protecting children in developing countries. Crucell's core
portfolio also includes a vaccine against hepatitis B and a virosome-adjuvanted
vaccine against influenza. Crucell also markets travel vaccines, such as an oral
anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free
hepatitis A vaccine on the market. The Company has a broad development pipeline,
with several product candidates based on its unique PER.C6(®) production
technology. The Company licenses its PER.C6(®) technology and other technologies
to the biopharmaceutical industry. Important partners and licensees include
Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and
Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with
subsidiaries in Argentina, China, Italy, Korea, Spain, Sweden, Switzerland, UK
and the USA. The Company employs over 1200 people. For more information, please
visit www.crucell.com
For further information please contact Crucell:
Oya Yavuz
Vice President Corporate Communications & Investor Relations
Tel. +31 (0)71 519 7064
ir(at)crucell.com
www.crucell.com
[HUG#1412155]
PDF file: http://hugin.info/132631/R/1412155/364441.pdf
Unternehmensinformation / Kurzprofil:
Datum: 06.05.2010 - 07:45 Uhr
Sprache: Deutsch
News-ID 20352
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 228 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem® by UNICEF to Support Vaccination Programs in the Developing World"
steht unter der journalistisch-redaktionellen Verantwortung von
Crucell N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
